Related Experiment Videos
Hepatitis B virus (HBV) markers among patients with chronic liver disease in Kuwait
Insights
Hepatitis B virus (HBV) infection is a significant factor in chronic liver disease development in Kuwait. Radioimmunoassay revealed high HBV marker prevalence in patients, indicating a major public health concern.
Area of Science:
- Hepatology
- Virology
- Epidemiology
Background:
- Chronic liver disease is a significant health issue in Kuwait.
- Hepatitis B virus (HBV) is a potential contributor to liver disease progression.
- Understanding HBV prevalence is crucial for public health strategies.
Purpose of the Study:
- To investigate the prevalence of key Hepatitis B virus (HBV) markers in patients with chronic liver disease.
- To compare HBV marker prevalence between patients and a healthy control group.
- To identify associations between HBV infection and specific liver conditions.
Main Methods:
- Radioimmunoassay (RIA) systems were employed to detect HBV markers.
- Prevalence of hepatitis B surface antigen (HBsAg), anti-HBc, and anti-HBs was assessed.
- Patient data was compared against a control blood donor population.
Main Results:
- 81% of patients and 44% of controls showed at least one HBV marker.
- 24% of patients exhibited markers indicative of chronic HBV infection.
- Higher prevalence of HBV markers was observed in patients with hepatosplenic schistosomiasis, cryptogenic cirrhosis, and hepatocellular carcinoma.
Conclusions:
- HBV infection is a major factor in the development of chronic liver disease in Kuwait.
- HBV plays a concomitant role in severe liver disease, particularly in patients with hepatosplenic schistosomiasis.
- Targeted interventions for HBV may be necessary in high-risk populations.
Abstract:
The prevalence of hepatitis B surface antigen (HBsAg), antibody to the hepatitis B core (anti-HBc) and to surface antigen (anti-HBs), was investigated, using sensitive radioimmunoassay (RIA) systems, among patients with different clinical entities of chronic liver disease in Kuwait, and compared to a control blood donor population. 81% of patients and 44% of the controls had at lease one HBV marker. 24% of patients, but non of the controls had both HBsAg and a high titre of anti-HBc in the absence of anti-HBs, suggesting a chronic infection. 31% of our patients with hepatosplenic schistosomiasis, 20% with cryptogenic cirrhosis and chronic active liver disease and 60% with hepatocellular carcinoma had these two markers. HBV antigenaemia was significantly more prevalent among male than among female patients and was particularly high among those less than 35 years old. The high prevalence of the various HBV markers among our patients suggests that HBV is a major factor in the development of chronic liver disease in our area. Furthermore, in view of a high prevalence of antigenaemia in patients with hepato-splenic schistosomiasis, HBV infection must play a concomitant role in the development of more serious form of chronic liver disease among such patients.